Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News CASI Pharmaceuticals Inc CASI

Healthcare Biotechnology
CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. Its... see more

Recent & Breaking News (NDAQ:CASI)

CASI Pharmaceuticals To Present At Jefferies London Healthcare Conference

PR Newswire November 15, 2021

CASI Pharmaceuticals Announces Third Quarter 2021 Financial Results

PR Newswire November 12, 2021

CASI Pharmaceuticals Partner, BioInvent, To Present Further Positive Clinical Data On BI-1206 At ASH 2021

PR Newswire November 5, 2021

CASI Pharmaceuticals To Report Third Quarter 2021 Financial Results And Host Conference Call November 12, 2021

PR Newswire November 2, 2021

CASI Pharmaceuti­­­cals Announces Partner Juventas Completion Of Series C Financing Of $63 Million (RMB410 Million) For Acceleration Of CNCT19 Pivotal Trials And Commercialization

PR Newswire October 25, 2021

CASI Pharmaceuticals, Inc. To Participate In Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

PR Newswire September 20, 2021

CASI Pharmaceuticals Announces Second Quarter 2021 Financial Results

PR Newswire August 12, 2021

CASI Pharmaceuticals To Report Second Quarter 2021 Financial Results And Host Conference Call August 12, 2021

PR Newswire August 10, 2021

CASI Pharmaceuticals Announces Dosing Of First Patient Of CID-103 In Phase 1 Clinical Trial For Relapsed Or Refractory Multiple Myeloma

PR Newswire June 10, 2021

CASI Pharmaceuticals, Inc. To Participate In Jefferies Virtual Healthcare Conference

PR Newswire May 27, 2021

INVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating CASI Pharmaceuticals, Inc. for Potential Breach of Fiduciary Duty Claims

ACCESSWIRE IA May 17, 2021

CASI Pharmaceuticals Announces First Quarter 2021 Financial Results

PR Newswire May 13, 2021

CASI Pharmaceuticals To Report First Quarter 2021 Financial Results And Host Conference Call May 13, 2021

PR Newswire May 11, 2021

CASI Pharmaceuticals Announces Full Year 2020 Financial Results

PR Newswire March 30, 2021

CASI Pharmaceuticals Announces Pricing Of $32,500,000 Public Offering Of Common Stock

PR Newswire March 24, 2021

CASI Pharmaceuticals Announces Proposed Public Offering Of Common Stock

PR Newswire March 23, 2021

CASI Pharmaceuticals To Host Business Update Call March 12, 2021

PR Newswire March 11, 2021

Cleave Therapeutics Licenses First-in-Class VCP/P97 Inhibitor CB-5339 To CASI Pharmaceuticals For Greater China Region

PR Newswire March 8, 2021

CASI Pharmaceuticals Announces Preliminary Fourth Quarter And Full-Year 2020 Revenues And Provides Business Updates

PR Newswire February 16, 2021

CASI Pharmaceuticals Partner, BioInvent, Presents Phase I/IIA Data That Suggests BI-1206 Restores Activity Of Rituximab In Relapsed Non-Hodgkin's Lymphoma Patients

PR Newswire January 28, 2021